BioVenture eLab will host Dr. Sara Glickstein Bar-Zeev (Ph.D. '00), principal clinical scientist in Genentech's gRED OMNI Early Clinical Development group, for a discussion on drug development and clinical research.
Drawing on her experience leading first-in-human and proof-of-concept clinical trials, Dr. Glickstein Bar-Zeev will explore how translational science helps reduce uncertainty in early drug development, the evolving clinical research landscape, and the growing opportunities for collaboration between academia and industry.
A Weill Cornell Medicine alumna with a doctorate in neurobiology, Dr. Glickstein Bar-Zeev joined Genentech in 2017 after a decade in medical communications focused on publication strategy and medical writing. She previously held research faculty appointments at Weill Cornell Medicine and Columbia University, completed fellowships in ophthalmology and psychiatry, and has authored more than 30 peer-reviewed publications.
Whether you are a researcher, clinician, student, or industry executive, this conversation will offer valuable insights into key decisions to be made during each phase of clinical development.